CMV immune globulin (CMVIG) should certainly not be first-line therapy for treating CMV syndromes. It can be considered for use in special circumstances when patients are intolerant to 1st or 2nd line therapy, they have resistant/refractory disease, or are at significant risk for morbidity in combin...